Doxofylline Dosing in Adults and Pediatrics
For adults with asthma, doxofylline is dosed at 400 mg three times daily (1200 mg/day total), while for pediatric patients aged 6 years and older, the recommended dose is 6 mg/kg twice daily (BID), not exceeding 400 mg per dose.
Adult Dosing
The standard adult dose is 400 mg three times daily (t.i.d.), which has been validated in multiple clinical trials 1, 2. This dosing regimen:
- Significantly improves FEV1 by approximately 16.9% from baseline
- Reduces asthma event rates and rescue medication use
- Demonstrates superior safety compared to theophylline 250 mg t.i.d.
- Does not require routine blood level monitoring
A lower dose of 200 mg t.i.d. showed minimal efficacy differences from placebo and is not recommended 2.
Pediatric Dosing
For children ≥6 years of age, the recommended dose is 6 mg/kg per dose twice daily (BID) 3, 4. In practical terms:
- The dose from the Mexican pediatric study used 18 mg/kg/day total (divided into doses throughout the day) 5
- Individual doses should not exceed 400 mg
- Available as 200 mg sachets for easier pediatric administration 6
Critical caveat: Doxofylline has not been adequately studied in children under 6 years of age. The retrospective safety data included children as young as 3 years, but prospective efficacy data is limited to those ≥6 years 6, 5.
Administration Details
- Timing: Can be taken without regard to meals, though specific meal restrictions noted in FDA labeling 7 appear to reference doxepin (a different drug), not doxofylline
- Monitoring: Unlike theophylline, routine plasma level monitoring is not required except in patients with hepatic insufficiency or xanthine intolerance 3
- Duration: Long-term use (up to 1 year) has been demonstrated as safe and effective 1
Safety Profile
Doxofylline demonstrates significantly better tolerability than theophylline:
- In pediatric populations, only 11% reported any side effects, with 5% reporting moderate effects and 5% discontinuing due to adverse events 6
- In adults, the most common adverse events were nausea (14.6%), headache (14.2%), insomnia (10.7%), and dyspepsia (10%) 1
- The number needed to treat to spare one dropout compared to theophylline is 5 2
Clinical Context
Doxofylline serves as an add-on bronchodilator therapy when inhaled corticosteroids alone are insufficient (asthma steps 3-4) 4. The pediatric study demonstrated that combining doxofylline with reduced-dose budesonide maintained lung function while improving asthma control, suggesting potential as a steroid-sparing agent 5. However, this steroid-sparing effect requires confirmation in longer-term controlled trials.
Important limitation: Doxofylline is not available in all markets, including the United States, where it lacks FDA approval for asthma treatment. The FDA drug labels provided 7 actually describe doxepin (a sleep medication), not doxofylline, highlighting the importance of verifying drug availability in your specific practice location.